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Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Many
kinases have been found to be intimately involved in oncogenesis and the deregulation of kinase function
has emerged as a major mechanism by which cancer cells evade normal physiological constraints on
growth and survival. Previously, we have performed gene expression proﬁle analysis on HCC samples and
have identiﬁed a host of kinases that are remarkably overexpressed in HCC. Among these, the Maternal
Embryonic Leucine Zipper Kinase (MELK) is highly overexpressed in HCC and its overexpression strongly
correlates with early recurrence and poor patients' survival. Silencing MELK inhibited cell growth, in-
vasion, stemness and tumorigenicity of HCC cells by inducing apoptosis and mitosis. We further showed
that the overexpression of MELK in HCC samples strongly correlated with the cell cycle- and mitosis-
related genes which are directly regulated as part of the forkhead transcription factor FoxM1-related
cell division program. Together, our data establish MELK as an oncogenic kinase involved in the path-
ogenesis and recurrence of HCC and could provide a promising molecular target to develop therapeutic
strategies for patients with advanced HCC.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatocellular carcinoma (HCC) is the most common type of
primary liver cancer and is the second leading cause of cancer-
related deaths worldwide [1,2]. Despite many attempts to develop
molecularly-targeted agents and immunotherapy strategies [3,4],olecular Research, National
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Ireland Ltd. This is an open accesssorafenib remains the only currently FDA-approved molecular in-
hibitor for the systemic therapy of advanced HCC. Hence, it is an
urgent unmet medical need to decipher the associated molecular
signaling pathways in hepatocarcinogenesis to facilitate the iden-
tiﬁcation of novel therapeutic targets to enable the development of
novel molecularly-targeted therapeutic strategies [5].
Many kinases have been found to be intimately involved in the
processes leading to tumor cell proliferation and survival and the
deregulation of kinase function has emerged as a major mecha-
nism by which cancer cells evade normal physiological con-
straints on growth and survival. Currently, a number of
therapeutic kinase inhibitors, including antibodies or small mol-
ecules that block the interactions between kinases and substrates,
and to inhibit the enzyme's adenosine triphosphate binding site
inhibitors, have already been developed and approved for cancerarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
H. Xia et al. / Cancer Letters 383 (2016) 85e9386treatment [6,7]. It is therefore a promising strategy to compre-
hensively identify and functional characterized oncogenic kinases
associated with HCC to enable the development of small molecule
kinase inhibitors for the molecularly-targeted treatment of HCC.
In this study, the expression of over 600 kinases were studied by
gene expression proﬁle analysis on HCC samples consisting of
patient samples with early recurrence (recurrent HCC disease
within two years) or non-recurrence (no recurrent disease after
ﬁve years) [8]. We have identiﬁed a host of HCC remarkablyFig. 1. MELK is highly overexpressed in HCC and its overexpression strongly correlates wit
signiﬁcantly up-regulated in HCC tissue samples of patients with early recurrent disease (R
histological histologically normal liver tissues (NN) (*P < 0.05 R vs NR, **P < 0.01 R þ NR vs M
of MELK was associated with poor recurrence-free survival of patients with HCC. (C) Validati
recurrence (T-NR), 40 matched normal (MN) and 10 histological histologically normal liver t
expression of MELK was associated with poor recurrence-free survival of patients with HCC.
in another panel of HCC tumor tissues (40). (F) The imaging analysis and quantiﬁcation of
cells with positive nuclei.overexpressed oncogenic kinases. Among them, the over-
expression of MELK is validated to be signiﬁcantly associated with
early HCC recurrence and poor patients' survival. While MELK has
been studied in many human cancers, its molecular roles in HCC
have not been elucidated. We have therefore further characterized
the functional roles of MELK in the pathogenesis of HCC and
demonstrating that MELK is a promising molecular target for the
development of molecularly-targeted therapeutic strategies
against HCC.h early recurrence and poor patients' survival. (A) The dotplot showed that MELK was
) compared to patients with non-recurrent disease (NR) and matched normal (MN) or
N þ NN). (B) The survival curve of 76 microarray samples showed that high expression
on of the expression of MELK by RT-qPCR in 20 tumor recurrence (TeR), 20 tumor non-
issues (NN). (D) The survival curve of 40 RT-qPCR validation samples showed that high
(E) The representative imaging of IHC staining for validation of the expression of EDIL3
IHC staining with EDIL3. The IHC images were evaluated according to the percentage of
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Cell lines, cell culture and tissues
The HuH7 cells were bought from Japanese Collection of Research Bioresources
(JCRB) Cell Bank (Osaka, Japan). HCCLM3 was a kind gift of Professor Zhao-You Tang
at the Liver Cancer Institute (Zhongshan Hospital, Fudan University, Shanghai) and
have been described previously [9]. The HCCLM3 has been authenticated using the
short tandem repeat (STR) proﬁling authentication test by Bio-Synthesis Inc (Lew-
isville, TX) while HuH7 has been tested by Genetica DNA Laboratories (Cincinnati,
OH). The cells were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM) with
10% FBS and 100 units/mL of penicillin and 100 mg/mL of streptomycin (Invitrogen,
Carlsbad, CA) at 37 C in the presence of 5% CO2. The collection of tissues from HCC
patients was approved by our Institutional Review Board (IRB). Written informed
consent was obtained from the participating patients, and relevant clinical and
histopathological data provided to the researchers were anonymized.
Animal studies
All mice experiments were approved by the SingHealth Institutional Animal
Care and Use Committee (IACUC). Stably transfected HCCLM3 cells were re-
suspended in PBS and subcutaneously implanted into the left and right ﬂanks
(5 106 cells per ﬂank) of male BALB/c nudemice. Tumor volumes were determined
each week by measuring their length (a) and width (b) using a vernier caliper. The
tumor volume (V) was calculated according to the formula V ¼ ab2/2. The statistical
signiﬁcance between tumor sizes in the shScramble and shMELK-transfected groups
was evaluated using the Student's t-test.
Additional Materials and Methods are provided in Supplementary Information.
Results
MELK is highly overexpressed in HCC and its overexpression strongly
correlates with early recurrence and poor patients' survival
To identify overexpressed oncogenic kinases in HCC, we
analyzed the expression of over 600 kinases in a gene expression
proﬁle dataset on early recurrence and non-recurrence HCC sam-
ples that we have previously established [8,10,11]. We have iden-
tiﬁed a panel of oncogenic kinases that are overexpressed in HCCTable 1
Association between MELK gene expression and clinic-pathological characteristics.
Clinical characteristics MELK
Low High
All cases 33 32
Gender
Male 29 29
Female 4 3
Age
<50 7 6
50 26 26
AFP
Negative 21 10
Positive 12 22
Differentiation
I/II 25 20
III/IV 8 12
Size
5 cm 19 20
>5 cm 14 12
Child-Pugh score
A 27 22
B 6 10
Cirrhosis
No 18 13
Yes 14 18
Venous Inﬁltration
NA 25 16
VI 8 16
Early Recurrence
No 21 8
Yes 12 24
Note: When expected count is less than 10, ﬁsher exact test was implemented. P value
association between MELK expression and clinic-pathological features. 0e0.30 is weak r(Fig. S1A). Among them, the expression of MELK was shown to be
signiﬁcantly up-regulated in HCC tumor tissues of patients with
early recurrence when compared with matched adjacent normal or
histologically normal liver tissues (Fig. 1A). The signiﬁcantly over-
expression of MELK in HCC was also observed when analyzed in
other published datasets such as GSE14520 (Fig. S1B) and The
Cancer Genome Atlas (TCGA) dataset (Fig. S1C).
The association between MELK expression level and the clinical
pathological characteristics was shown in Table 1. When the me-
dian expression level of MELK in the HCC samples studied in our
microarray analysis was chosen as the cut-off point, Fisher's exact
test and KaplaneMeier analysis showed that high expression of
MELK in HCC tissues was signiﬁcantly associated with shorter
overall survival in patients (Fig. 1B). These results were further
validated by qRT-PCR analysis in an independent cohort of HCC
samples comprising of 20 T-R: tumor with early recurrence; 20 T-
NR: tumor non-recurrence; 40 MN: matched adjacent normal; and
10 histologically normal liver tissues (Fig. 1C and D). The expression
ofMELKwas further studied in an independent cohort of 20 pairs of
HCC tumor tissues by IHC staining and it was further demonstrated
that MELK protein expression was also signiﬁcantly increased in
HCC tumors compared to matched normal tissues (Fig. 1E and F).
Knockdown of MELK inhibited cell viability and induces apoptosis
and mitosis in HCC cells
MELK was relative low expressed in most of the normal human
tissues when studied, including normal adult liver (Fig. S2A and
S2B). In comparison, MELK was overexpressed in many human
tumor tissues when analyzed using the TCGA dataset (Fig. S2C).
While MELK has been studied in many human cancers, its molec-
ular roles in HCC have not been elucidated. To decipher the bio-
logical function of MELK in HCC, we applied a loss-of-functionx2 or ﬁsher exact test P value Cramer's V
1
1
6.831 0.009 0.324
0.29
0.164 0.685
0.260
1.291 0.256
4.628 0.031
9.815 0.002 0.38
<0.05 is considered as statistically signiﬁcant. The Cramer's V tells how strong the
elationship, 0.31e0.70 is moderate relationship, 0.71e1 is strong relationship.
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knockdown effects via endoribonuclease-prepared siRNAs (esiRNA)
targeted MELK was examined by RT-qPCR analysis (Fig. 2A).
Knockdown of MELK signiﬁcantly reduced HuH7 and HCCLM3 cell
viability after 72 h of transient transfection (Fig. 2B). Moreover,
transient knockdown of MELK in HuH7 and HCCLM3 cells signiﬁ-
cantly increased the detectable Annexin V-positive apoptotic cells
as measured by multi-parametric ﬂow cytometry for Annexin V inFig. 2. Knockdown of MELK inhibits cell viability and induces apoptosis and mitosis in H
(esiMELK) or esiControl by RT-qPCR. (B) The normalized relative cell viability of HuH7 and
increase in Annexin-Vþ cells was observed by ﬂow cytometry analysis in both HuH7 and H
analysis images showed that knockdown of MELK increases the phospho-histone H3 (M
transfection.combination with the nuclear dye 7-aminoactinomycin D (7-AAD)
(Fig. 2C).
Phosphorylation at a highly conserved serine residue (Ser-10) in
the histone H3 tail is considered to be a crucial event for the onset of
mitosis and it has been suggested that MELK is an oncogenic kinase
essential for mitotic progression. We then examined the effect of
MELK knockdown on HCC cell mitosis arrest. Confocal immuno-
ﬂuorescent studies showed that knockdown of MELK increased theCC cells. (A) The knockdown effects of MELK in HuH7 and HCCLM3 by MELK esiRNA
HCCLM3 cells at 72 h of MELK knockdown. (C) The represent images showed that the
CCLM3 cells with esiMELK transfection. (D) The represent confocal immunoﬂuorescent
itotic Marker) positive cell number in both HuH7 and HCCLM3 cells with esiMELK
H. Xia et al. / Cancer Letters 383 (2016) 85e93 89numbers of positive cells with anti-phospho histone H3 (Ser-10)
staining (Fig. 2D), suggesting inhibition of MELK causes mitotic ar-
rest, which led to an increase of mitosis marker, phospho-Histone
H3 (Ser-10). These data indicated that knockdown of MELK re-
duces cell viability and induces apoptosis and mitosis in HCC cells.
Silencing MELK inhibits the proliferation and tumorigenicity of HCC
cells
Next, we generated stable knockdown cells of MELK by trans-
fecting HCCLM3 and HuH7 cells with validated MISSION shRNA of
MELK (TRCN0000280028). Following transfection and selection
with puromycin, the expression of MELK in stably transfectedFig. 3. Silencing MELK inhibits proliferation and tumorigenicity of HCC cells. (A) The stabl
stable knockdown effect of MELK in HuH7 and HCCLM3 cells by western blotting analysis. (
proliferation in soft agar in HuH7 and HCCLM3 with stable knockdown of MELK. (E) Represen
control-treated HCCLM3 cells, n ¼ 5. The xenografts in the left and right ﬂanks are labeledHCCLM3 and HuH7 cells were signiﬁcantly decreased (Fig. 3A and
B). To test the speciﬁcity of this validated shRNA and esiRNA, we
investigated to rescue the cell viability inhibition phenotype of
MELK knockdown by introducing active MELK protein into the cell
to out-compete the knockdown effects. The results showed that
rescue MELK by introducing the active MELK protein can overcome
MELK esiRNA or shRNA caused cell viability inhibition (Fig.S3A).
Soft agar colony formation assays demonstrated that silencing of
MELK efﬁciently inhibited the ability of HCC cells to proliferate in
semi-solid matrices (Fig. 3C and D). We next compared the
tumorigenicity of HCCLM3 cells stably transfected with either
shMELK or shScramble in Ncr nude mice. It was observed that
stably knockdown of MELK in HCCLM3 cells signiﬁcantly inhibitede knockdown effect of MELK in HuH7 and HCCLM3 cells by RT-qPCR analysis. (B) The
C and D) The represent images (C) and number of colony counting statistics (D) of cell
tative image and (F) growth curve of xenografts with stably MELK-silenced or scramble
, indicating shScramble or shMELK, respectively.
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stemness of anti-tumor data with MELK shRNA. Our preliminary
data demonstrated that the expression of both CD44 and CD133,
putative cancer stem cell-related markers in HCC, were decreased
in shMELK-transfected tumor tissues compared to shScramble-
transfected tumors in vivo by immunohistochemistry (IHC) stain-
ing of mice tumor tissue samples (Fig. S3B).
Silencing MELK inhibits cell invasion and stemness property of
HCC cells
Transwell invasion assays showed that stably knockdown of
MELK in HuH7 and HCCLM3 cells decreased their invasion ability asFig. 4. Silencing MELK inhibits cell invasion and stemness property of HCC cells. (A and B
statistics (B) in HuH7 and HCCLM3 with stable knockdown of MELK. (C and D) The represen
HuH7 and HCCLM3 with stable knockdown of MELK. (EeH) The effects of MELK stable kno
HCCLM3 (E, F) and HuH7 (G, H) with stable knockdown of MELK (*P < 0.05, **P < 0.01).compared to the respective shScramble-transfected control cells
(Fig. 4A and B). Cancer stem cells (CSCs) are thought to contribute to
tumor recurrence and metastasis. However, for many cancers
including HCC, speciﬁcmakers have not beenwell-deﬁned for CSCs,
sphere-forming ability has been emerged as a surrogate to evaluate
the stemness characteristics of cells. We have therefore evaluated
HuH7-shMELK and HCCLM3-shMELK cells for their ability to form
tumor spheres. It was observed that HuH7-shMELK and HCCLM3-
shMELK cells generated 2~3-fold fewer spheres than their corre-
sponding shScramble-transfected control cells (Fig. 4C and D). Flow
cytometric analysis further demonstrated that HuH7-shMELK and
HCCLM3-shMELK cells gave a decreased CD44þ/CD133þ double
positive cell subpopulation (Fig. 4E and F). CD44 and CD133 have) The represent transwell invasion images (A) and number of migrated cells counting
t sphere formation images (C) and number of tumor spheres counting statistics (D) in
ckdown on the cancer stem-like CD44þ, CD133þ and CD44þCD133þ cell population in
H. Xia et al. / Cancer Letters 383 (2016) 85e93 91been reported as potential biomarkers of HCC CSCs and thus pro-
vide corroborative evidence for silencing MELK reduce the stem-
ness property of HCC cells.
MELK is highly expressed in stem-like HCC cells and associated with
self-renewal capacity
To critically evaluate the role of MELK in the self-renewal of
stem-like HCC CSCs, we isolated the CD44þCD133þ cell population
from HuH7 cells by ﬂuorescence-activated cell sorting (Fig. 5A).
The CD44þCD133þ HCC cells have been shown to be highly
enriched with cancer stem/progenitor cells with stem cell-like
properties including extensive proliferation, self-renewal, differ-
entiation into the bulk of cancer cells and responsible for the
hematogenous metastasis of liver cancers [12,13]. Analysis by qRT-Fig. 5. MELK is highly expressed in stem-like HCC cells and associated with self-renewal ca
CD44CD133 cell population from HuH7 cells using ﬂuorescence-activated cell sorting (
CD44þCD133þ and CD44CD133 cell population by RT-qPCR analysis. (E) The represent sp
represent sphere formation images of the CD44CD133 cells with overexpression of MELK
analysis. (H) The represent ﬂow cytometry images for the analysis the CD44 and CD133 poPCR validated that the expression of CD44 and CD133 was much
higher in the CD44þCD133þ cells than the CD44CD133 cells
(Fig. 5B and C). Interesting, it was also observed that the expres-
sion of MELK was also much higher in the CD44þCD133þ cells
than the CD44CD133 cells, suggesting MELK may play an
important role in the self-renewal of HCC CSCs cells (Fig. 5D).
Results of the sphere formation assays also showed that
CD44þCD133þ cells have higher sphere formation ability than the
CD44CD133 cells (Fig. 5E and F). Importantly, overexpression of
MELK in CD44CD133 cells signiﬁcantly promoted the sphere
formation ability of CD44CD133 cells and to increase the
number of detectable CD44þ and CD133þ cells (Fig. 5G and H).
These data indicated that MELK is highly expressed in stem-like
HCC CSCs cells and potentially associated with self-renewal
capacity.pacity. (A) The represent ﬂow cytometry images for isolation of the CD44þCD133þ and
FACS). (BeD) The examination of CD133 (B), CD44 (C) and MELK (D) in the isolated
here formation images of the isolated CD44þCD133þ and CD44CD133 cells. (F) The
by pLenti-MELK transfection. (G) The number of tumor spheres counting and statistics
sitive cell population.
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through FOXM1 pathway
To decipher the critical functional role of MELK and to map out
its interactome in HCC, we have chosen to identify genes that are
strongly associated with MELK using our previously established
gene expression proﬁling dataset of HCC samples from patients
with early recurrent disease. There are 26 genes with a strong
correlation to MELK (r > 0.8) using Pearson correlation analysis
(Fig. 6A). Ingenuity Pathway Analysis (IPA) indicated that the
function of these genes are mainly related to cell cycle G2/M DNA
damage checkpoint regulation, mitotic roles of Polo-like kinase,
cyclins and cell cycle regulation pathways (Fig. 6B, S4A and S4B).
Moreover, out of the 26 genes, seven genes are predicted to be
regulated by the forkhead transcription factor FoxM1 using IPA, oneFig. 6. MELK interacts with FOXM1 to regulate the cell cycle progression and mitosis-rela
correlation (r) analysis (r > 0.8) in our genomic proﬁle dataset of HCC patients' samples. (B) T
in HCC compared with matched normal samples. (C) The MELK correlated cell cycle progre
transcription factor FOXM1 by IPA analysis.of the 26 genes that are strongly correlated to MELK (Fig. 6C),
suggesting the likely possibility that MELK regulates the cell cycle
related genes andmitotic progression through the FOXM1 pathway.
Discussion
Being a member of the AMPK/Snf1 family, MELK was initially
cloned from mouse (Mus musculus) using differential display
analysis of cDNA libraries from unfertilized eggs and preimplan-
tation embryos [14]. It has been reported that MELK is frequently
and highly up-regulated in various types of human cancer ac-
cording to the TCGA dataset, and that elevated MELK expression is
correlated with poor prognosis of cancer patients [15]. However,
the critical role of MELK in the carcinogenic process of HCC has not
been studied. Here, we demonstrated that MELK functions as ated genes. (A) The 26 genes have a strong correlation to MELK according to Pearson
he MELK correlated cell cycle progression and mitosis-related genes are overexpressed
ssion and mitosis-related genes are predicted to be mainly regulated by the correlated
H. Xia et al. / Cancer Letters 383 (2016) 85e93 93recurrence-related oncogenic kinase in HCC. The overexpression of
MELK strongly correlates with early HCC recurrence and poor sur-
vival. The mRNA expression of MELK is low (but still detectable) in
normal tissue include normal liver by qRT-PCR. The expression of
MELK is also demonstrated in the results of The Human Protein
Atlas (HPA) project (Fig. S5A). However, in the HPA dataset, it is also
demonstrated that the mRNA expression of MELK and protein
expression of MELK may not be consistent for certain tissue types
(Fig. S5B). This currently presents a controversy and may suggest
that the IHC reagents are not highly speciﬁc or post-transcriptional
regulation such as microRNA regulation and which are being
investigated. Our data suggest MELK is a potentially druggable
target for HCC. Ultimately, MELK will need to be fully validated in
clinical studies. A more comprehensive analysis of the underlying
mechanisms of these toxicities will undoubtedly give more new
insights into how to better select the optimal patient candidates for
MELK-based therapies. The application of small molecule to inhibit
MELK as potential strategies to treat HCC using pre-clinical ortho-
topic xenograft models for HCC is being explored.
We have investigated the roles of MELK in the growth of HCC
cells by both loss-of-function and gain-of-function approaches. We
found that silencing of MELK reduced cell viability and proliferation
and induced apoptosis and mitosis of HCC cells. Stably silencing of
MELK inhibited cell invasion, stemness and tumorigenicity of HCC
cells. Recent studies suggest that activation of MELK is tightly
associated with extended survival and accelerated proliferation of
glioma stem cells [16,17]. The CD44þCD133þ HCC cells have been
shown to be highly enriched with properties of cancer stem/pro-
genitor cells [12,13]. We isolated the CD44þCD133þ cells from the
cultured HuH7 cell population and demonstrated that
CD44þCD133þ cells exhibitedmuch higher sphere formation ability
than CD44CD133 cells and a concomitant overexpression of
MELK. Importantly, overexpression of MELK in CD44CD133 cells
signiﬁcantly promoted the sphere formation ability of
CD44CD133 cells and to further suggest that overexpression of
MELK in HCC cells is potentially associated with its stemness
properties. Cancer cell heterogeneity fueled by the inherent di-
versity of biological systems including mutations, clonal evolution,
genomic instability, epigenetic changes and interactions with
microenvironment, is now known to inﬂuence important differ-
ences in molecular phenotypes between cells within the same
patient and tumor. With this in mind, MELK-based agents devel-
oped may have limited effects on cancer cells that are not dividing
at a particular point in time during treatment, but nevertheless,
these cells might awaken at some point during the treatment
period and the apparent successful eradication of cancer may be
achievable. Moreover, the recent recognition of a small population
of cancer stem cells which has a more malign behavior and offers
the perfect treatment targets. The characterization of cancer stem
cells between recurrent and non-recurrent HCC patients in the
context of MELK expression are in progress.
We further demonstrated that MELK exerted its oncogenic roles
in association with the FOXM1 pathway in HCC cells. FOXM1 is a
master regulator of cell cycle progression and is overexpressed in a
number of human cancers including HCC. Its expression is found to
be highly correlated with MELK in this study. FOXM1 is a down-
stream component of Wnt signaling and is critical for b-catenin
transcriptional function in tumor cells. Wnt/b-catenin signaling is
essential for stem cell regulation and tumorigenesis. The high fre-
quency of beta-catenin mutations and aberrant activation of the
canonical Wnt signaling are frequently observed in HCC. High nu-
clear b-catenin and c-Myc expression correlated with vascular in-
vasion and reduced recurrence-free survival, suggesting the
involvement of Wnt signaling activation in promoting HCC recur-
rence and stemness [18]. Therefore, MELK could play a role duringhepatocarcinogenesis through interactions with the FOXM1/b-
catenin pathway. In summary, MELK can be a potentially novel
oncogenic driver of HCC and provide a promising target for small
molecule-based therapeutic interventions.Acknowledgements
We are grateful to the SingHealth Flow Cytometry Core Platform
for the ﬂow cytometry analysis and cell sorting. This work was
supported by grants from the SingHealth Foundation (SHF/FG532P/
2013) and the National Medical Research Council of Singapore
(NMRC/CBRG/0054/2013, NMRC/BNB/0009B/2013).Conﬂict of interest
The authors declare no conﬂict of interest.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.canlet.2016.09.017.References
[1] M. Maluccio, A. Covey, Recent progress in understanding, diagnosing, and
treating hepatocellular carcinoma, CA Cancer J. Clin. 62 (2012) 394e399.
[2] L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global
cancer statistics, 2012, CA Cancer J. Clin. 65 (2015) 87e108.
[3] M.F. Sprinzl, P.R. Galle, Facing the dawn of immunotherapy for hepatocellular
carcinoma, J. Hepatol. 59 (2013) 9e10.
[4] M.-A. W€orns, P.R. Galle, HCC therapiesdlessons learned, Nat. Rev. Gastro-
enterol. Hepatol. 11 (7) (2014 Jul) 447e452.
[5] J. Bruix, T. Takayama, V. Mazzaferro, G.-Y. Chau, J. Yang, M. Kudo, et al.,
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation
(STORM): a phase 3, randomised, double-blind, placebo-controlled trial,
Lancet Oncol. 16 (2015) 1344e1354.
[6] P. Wu, T.E. Nielsen, M.H. Clausen, FDA-approved small-molecule kinase in-
hibitors, Trends Pharmacol. Sci. 36 (7) (2015 Jul) 422e439.
[7] S. Gross, R. Rahal, N. Stransky, C. Lengauer, K. Hoeﬂich, Targeting cancer with
kinase inhibitors, J. Clin. Investig. 125 (2015) 1780e1789.
[8] H. Xia, C. Jianxiang, M. Shi, H. Gao, S. Karthik, S.V. Pratap, et al., EDIL3 is a novel
regulator of epithelial mesenchymal transition controlling early recurrence of
hepatocellular carcinoma, J. Hepatol. 63 (2015) 863e873.
[9] Y. Li, Z. Tang, S. Ye, B. Liu, Y. Liu, J. Chen, et al., Establishment of a hepato-
cellular carcinoma cell line with unique metastatic characteristics through
in vivo selection and screening for metastasis-related genes through cDNA
microarray, J. Cancer Res. Clin. Oncol. 129 (2003) 43e51.
[10] S.M. Wang, L.L.P. Ooi, K.M. Hui, Identiﬁcation and validation of a novel gene
signature associated with the recurrence of human hepatocellular carcinoma,
Clin. Cancer Res. 13 (2007) 6275e6283.
[11] H. Xia, L.L.P.J. Ooi, K.M. Hui, MicroRNA-216a/217-induced epithelial-
mesenchymal transition targets PTEN and SMAD7 to promote drug resis-
tance and recurrence of liver cancer, Hepatology 58 (2013) 629e641.
[12] Z. Zhu, X. Hao, M. Yan, M. Yao, C. Ge, J. Gu, et al., Cancer stem/progenitor cells
are highly enriched in CD133þCD44þ population in hepatocellular carcinoma,
Int. J. Cancer 126 (2010) 2067e2078.
[13] Y. Hou, Q. Zou, R. Ge, F. Shen, Y. Wang, The critical role of CD133þ CD44þ/
high tumor cells in hematogenous metastasis of liver cancers, Cell Res. 22
(2012) 259e272.
[14] R. Ganguly, A. Mohyeldin, J. Thiel, H.I. Kornblum, M. Beullens, I. Nakano,
MELKda conserved kinase: functions, signaling, cancer, and controversy, Clin.
Transl. Med. 4 (2015).
[15] H. Inoue, T. Kato, S. Olugbile, K. Tamura, S. Chung, T. Miyamoto, et al., Effective
growth-suppressive activity of maternal embryonic leucine-zipper kinase
(MELK) inhibitor against small cell lung cancer, Oncotarget 7 (12) (2016 Mar
22) 13621e13633.
[16] K. Joshi, Y. Banasavadi-Siddegowda, X. Mo, S.H. Kim, P. Mao, C. Kig, et al.,
MELK-dependent FOXM1 phosphorylation is essential for proliferation of
glioma stem cells, Stem cells 31 (2013) 1051e1063.
[17] I. Nakano, K. Joshi, K. Visnyei, B. Hu, M. Watanabe, D. Lam, et al., Siomycin A
targets brain tumor stem cells partially through a MELK-mediated pathway,
Neuro Oncol 13 (2011) 622e634.
[18] J. Chen, M. Rajasekaran, H. Xia, X. Zhang, S.N. Kong, K. Sekar, et al., The
microtubule-associated protein PRC1 promotes early recurrence of hepato-
cellular carcinoma in association with the Wnt/b-catenin signalling pathway,
Gut (2016), http://dx.doi.org/10.1136/gutjnl-2015-310625.
